{"entity":{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 2 trial of TGRX-326 in non-small-cell lung cancer and small-cell lung cancer, run by Shenzhen TargetRx Co., Ltd., active and no longer recruiting.","summary":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05955391 by Shenzhen TargetRx Co., Ltd., with 164 participants enrolled, started 2023-01-18 and due to reach its primary completion in 2024-12-29. Interventions recorded: TGRX-326. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05955391","url":"https://clinicaltrials.gov/study/NCT05955391"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","alk-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tgrx-326"],"companies":["shenzhen-targetrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05955391-j-thorac-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05955391","phase":"2","setting":"A Multi-centered, Open-label, Single-arm Phase II Study to Evaluate the Safety and Efficacy of TGRX-326 Monotherapy in Patients of Advanced ALK-positiveNon-Small Cell Lung Cancer Who Failed 2nd-Generation ALK Inhibitor Therapies","sponsor":"Shenzhen TargetRx Co., Ltd.","started":"2023-01-18","startedType":"actual","enrolled":164,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05955391/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/"}],"company":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/"}],"paper":[{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/"}]}}